Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Hudson Bay Capital Management LP cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,791 shares of the biopharmaceutical company’s stock after selling 31,367 shares during the period. Hudson Bay Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $19,000,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $628,151,000. AQR Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after buying an additional 606,612 shares in the last quarter. Invesco Ltd. increased its holdings in Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after buying an additional 408,649 shares during the period. Finally, Loomis Sayles & Co. L P increased its holdings in Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 over the last quarter. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Down 2.0%

REGN opened at $744.12 on Thursday. The company has a market cap of $78.67 billion, a P/E ratio of 17.90, a PEG ratio of 2.04 and a beta of 0.41. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $767.89 and its 200-day moving average is $698.50. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company earned $12.07 EPS. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Analyst Ratings Changes

REGN has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Oppenheimer restated an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.